Jazz Pharmaceuticals (Nasdaq: JAZZ) is rocking! The company blew away fourth-quarter estimates, posting an impressive $0.56 per share compared to a $0.17 per share number same time last year.� Revenue surged more than 40% to $53.4 million from $38.3 million.� More importantly, Jazz has ramped up its full year 2011 adjusted profit figures to between $2.70 and $2.90 per share.� What is driving this pharma company to these stellar returns?
A jump in sales for its Xyrem and Luvox CR products is behind the advance.� Xyrem is a daytime sleepiness drug for patients with narcolepsy and cataplexy.� Luvox CR treats obsessive compulsive and social anxiety disorders.
Headed by CEO, Bruce Cozadd, Jazz is a specialty pharmaceutical company that develops and commercializes products for neurology and psychiatry primarily in the United States. The company’s marketed products include Xyrem, a sodium oxybate oral solution for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy; and Luvox CR for obsessive compulsive disorder and social anxiety disorder. The company’s late-stage product candidate comprises JZP-6, which has completed two phase III pivotal clinical trials, for the treatment of fibromyalgia. Its other product candidates in clinical development consist of JZP-8, an intranasal formulation of clonazepam for the treatment of recurrent acute repetitive seizures in epilepsy patients who continue to have seizures while on stable anti-epileptic regimens; JZP-4, a controlled release formulation of an anticonvulsant for the treatment of epilepsy and bipolar disorder; and JZP-7, a transdermal gel formulation of ropinirole for the treatment of restless legs syndrome. In addition, the company is developing oral tablet forms for sodium oxybate.
Taking a close look at the technicals, the daily chart paints a near perfect uptrend from September, 2010.� Price is substantially above both the 50 and 200-day moving averages with very few pullbacks.� Trend traders must love this stock!
No comments:
Post a Comment